GLP-1 receptor agonist: difference between revisions
Diff·revision 8 → 9·07:42, 23 Aug 2024
Difference between revision 8 and revision 9 of GLP-1 receptor agonist. 3 lines changed; the page grew by 492 bytes.
| Revision 8 — 02:39, 14 Aug 2024 FigureFerdinand (talk) give the isoelectric point with the method it was determined by 4,921 bytes +740 | Revision 9 — 07:42, 23 Aug 2024 CagriCass (talk) alphabetise the see-also list 5,413 bytes +492 | ||
|---|---|---|---|
| 34 | | Fc fusion | [[Dulaglutide]] | 90 h | Reduced renal clearance, FcRn recycling | | 34 | | Fc fusion | [[Dulaglutide]] | 90 h | Reduced renal clearance, FcRn recycling | |
| 35 | 35 | ||
| + | 36 | [[Albumin binding half-life extension|Albumin binding]] is the dominant approach because it is reversible: the bound fraction acts as a circulating depot from which free drug is released continuously, flattening the peak-to-trough ratio as well as extending exposure. The C-18 diacid used in semaglutide binds albumin more tightly than the C-16 monoacid used in liraglutide, which is the principal reason for the difference in dosing interval.{{r|knudsen2019}} | |
| + | 37 | ||
| 36 | == References == | 38 | == References == |
| 37 | {{reflist}} | 39 | {{reflist}} |
| ⋮ | ⋮ | ||
| 45 | [[Category:Peptide drugs]] | 47 | [[Category:Peptide drugs]] |
| 46 | [[Category:Receptor pharmacology]] | 48 | [[Category:Receptor pharmacology]] |
| + | 49 | [[Category:Pharmacokinetics]] | |
| 47 | 50 |